See exactly where the price sits versus its 150-day moving average, the live RSI reading, MACD momentum, and volume context, for any ticker, every day.
Where DMAAU stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DMAAU finished 4.82% above its 150-day moving average ($10.78) and 5.51% above its 200-day moving average ($10.71). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DMAAU overbought or oversold?
At the October 20, 2026 close, DMAAU's RSI(14) was 100.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Key stats
52W Change+6.3%
Dividend Yield0.00%
Analysis
Drugs Made In America Acquisition Corp. carries $350K in total debt against $20K in cash reserves — debt is roughly 17.3x the cash position. Managing this leverage effectively will be important for long-term financial stability.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing DMAAU's risk profile alongside its fundamentals and technical indicators provides a more complete picture.
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms